Terracom (TER.AX) traded down -5.66 % during a 24 hours period ending at 10:58 PM Central Europe on Monday 26th. One Terracom stock can currently be bought for about AUD 0.04 on popular exchanges. Current supply of Terracom stocks is 1.8 bn. Terracom has a current market capitalization of AUD 83.8 mn and approximately AUD 419.7 k worth of Terracom was traded on exchanges in the last 24 hours. Since last month end, Terracom has traded -36.71 % down. Simple moving average of last 200 days is at AUD 0.07. The highest price of past 52 weeks was recorded at AUD 0.12 on 03/23/2026. 52 weeks low was at AUD 0.05 on 10/23/2026.
Here is how related stocks have performed in the past 24 hours:
Fortifai (FTI.AX) traded down -15.94 % and now trades at AUD 0.3. Current market capitalisation for Fortifai is AUD 100.5 mn. FortifAI Limited (ASX: FTI) reported a decline in share price during the day, falling to an intraday low of A$0.290. The stock’s 30‑day and one‑year percentage changes were negative, with a market capitalization of approximately A$100 million. No further corporate actions or earnings announcements were disclosed. No other company‑specific news was linked to FortifAI in the provided sources.
Geopacific (GPR.AX) traded up 11.11 % and now trades at AUD 0.02. Geopacific has a market capitalisation of AUD 96.8 mn. GEOPACIFIC RESOURCES LTD announced its upcoming annual general meeting, scheduled for 25 November 2026, where shareholders will vote on several key corporate matters. The company will present its annual financial report and related documents, including the remuneration report and auditor’s statement. Shareholders will consider the re‑election of director Scott Williamson and the election of newly appointed directors Warrick Clent and Rob Curtis, both of whom bring extensive mining and exploration experience. The board will seek approval for a 7.1A mandate, allowing the company to issue additional equity securities without further shareholder consent, subject to a 75% affirmative vote. Additionally, shareholders will vote on the issuance of zero‑exercise price options to several directors, a move intended to align executive incentives with shareholder interests. No other material business is proposed at this meeting.
Iondrive (ION.AX) traded down -11.63 % and now trades at AUD 0.08. Iondrive has a market capitalisation of AUD 99.5 mn. IONDRIVE LTD held its annual general meeting on 27 November 2026, where shareholders reviewed a range of governance and remuneration matters. The board presented a comprehensive agenda that included the adoption of the remuneration report, the re‑election of Director Hugh Keller, and proposals for the issuance of ordinary shares to directors in lieu of a portion of their fees. Shareholders were also asked to approve the use of a 10 % placement facility, which would allow the company to raise additional equity under the ASX Listing Rule 7.1A. Additionally, the board sought approval for the grant of performance rights to Chief Executive Officer Dr Andrew Tong and to non‑executive directors, aligning long‑term incentives with shareholder value. The resolutions were framed to satisfy listing and corporate governance requirements, with voting exclusions applied where necessary. The meeting concluded without any substantive opposition, and shareholders were encouraged to review the full explanatory memorandum and related documents before casting their votes.
Island (ILA.AX) traded up 1.56 % and now trades at AUD 0.31. Current market capitalisation for Island is AUD 96.2 mn. Island Pharmaceuticals Limited reported progress on its Galidesivir program during the quarter ended 30 September 2026. The company secured government and regulatory approvals for compassionate use of Galidesivir in patients affected by the Bundibugyo Ebola outbreak in Uganda, creating an opportunity to gather prospective human data. A dose‑optimisation study with Texas Biomedical Research Institute was launched, complementing a similar programme at USAMRIID; together these studies aim to strengthen the evidence package for the FDA Animal Rule pathway for Marburg virus disease. Manufacturing activity continued with a second GMP‑grade Galidesivir campaign, expanding the inventory to support outbreak response and future studies. The company also obtained a Singapore patent covering ISLA‑101 for flavivirus treatment, broadening its intellectual‑property portfolio. Financially, the company ended the quarter with cash and equivalents of about $7.8 million. Operating cash outflows were largely driven by research and development, manufacturing and regulatory activities, while financing cash flow was modest, reflecting option exercise proceeds. Overall, Island is advancing multiple development tracks and expanding its manufacturing and regulatory foundations for Galidesivir and ISLA‑101.
Marmota (MEU.AX) traded down -2.67 % and now trades at AUD 0.08. Marmota has a market capitalisation of AUD 94.6 mn.
About Terracom
TerraCom Ltd. is an energy sector company based in Clermont, Australia, that specializes in providing coal mining services. The company offers hard coking, thermal, and PCI coals globally. Their website is www.terracomresources.com and they are listed on the ASX All Markets stock exchange.
